EcoDrugPlus

Bcl2 Like 1

Ensembl ID : ENSCGOG00000015487
Gene Symbol: BCL2L1
3 Cross references
229 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSCGOG00000001425
Gene Symbol: BCL2L1
3 Cross references
216 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSCGOG00000021640
Gene Symbol: BCR
3 Cross references
209 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSCGOG00000013012
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSCGOG00000023289
Gene Symbol: CCR9
3 Cross references
194 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSCGOG00000013347
Gene Symbol: CXCR1
1 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSCGOG00000005904
Gene Symbol: CXCR4
3 Cross references
216 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSCGOG00000009291
Gene Symbol: LOC115021026
2 Cross references
356 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCGOG00000012633
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

D(1)-Like Dopamine Receptor

Ensembl ID : ENSCGOG00000007335
Gene Symbol: LOC115019461
3 Cross references
201 Possible Orthologues:

D(3) Dopamine Receptor-Like

Ensembl ID : ENSCGOG00000015054
Gene Symbol: LOC115025802
3 Cross references
201 Possible Orthologues:

D(3) Dopamine Receptor-Like

Ensembl ID : ENSCGOG00000015050
Gene Symbol: LOC115025762
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).